{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:09:08Z","timestamp":1789016948006,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10620-026-09948-w","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:55:10Z","timestamp":1779692110000},"page":"5200-5212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pairwise Comparative Safety and Effectiveness of Anti-TNF Blockers, Vedolizumab, and Ustekinumab During Pregnancy: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"71","author":[{"given":"Omotayo","family":"Segun-Omosehin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie E.","family":"Bourdakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosta G.","family":"Tzanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Michele","family":"Macaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fares","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha A.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"9948_CR1","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ueg2.12319","volume":"10","author":"N Singh","year":"2022","unstructured":"Singh N, Bernstein CN. Environmental risk factors for inflammatory bowel disease. United European Gastroenterol J 2022;10:1047\u20131053.","journal-title":"United European Gastroenterol J"},{"key":"9948_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00384-024-04711-x","volume":"39","author":"D Lin","year":"2024","unstructured":"Lin D, Jin Y, Shao X, Xu Y, Ma G, Jiang Y, Xu Y, Jiang Y, Hu D. Global, regional, and national burden of inflammatory bowel disease, 1990\u20132021: insights from the global burden of disease 2021. Int J Colorectal Dis 2024;39:139.","journal-title":"Int J Colorectal Dis"},{"key":"9948_CR3","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41575-023-00758-3","volume":"20","author":"MN Brondfield","year":"2023","unstructured":"Brondfield MN, Mahadevan U. Inflammatory bowel disease in pregnancy and breastfeeding. Nat Rev Gastroenterol Hepatol 2023;20:504\u2013523.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"9948_CR4","doi-asserted-by":"publisher","first-page":"175628482412494","DOI":"10.1177\/17562848241249440","volume":"17","author":"F Zingone","year":"2024","unstructured":"Zingone F, Borsato A, Maniero D, Della Loggia F, Lorenzon G, Zanini A, Canova C, Barberio B, Savarino EV. Impact of inflammatory bowel disease on women\u2019s reproductive life: a questionnaire-based study. Therap Adv Gastroenterol 2024;17:17562848241249440.","journal-title":"Therap Adv Gastroenterol"},{"key":"9948_CR5","first-page":"579","volume":"33","author":"MF Ali","year":"2020","unstructured":"Ali MF, He H, Friedel D. Inflammatory bowel disease and pregnancy: fertility, complications and treatment. Ann Gastroenterol 2020;33:579\u2013590.","journal-title":"Ann Gastroenterol"},{"key":"9948_CR6","first-page":"96","volume":"11","author":"JG Hashash","year":"2015","unstructured":"Hashash JG, Kane S. Pregnancy and Inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2015;11:96\u2013102.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"9948_CR7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.cgh.2010.02.014","volume":"8","author":"O Stephansson","year":"2010","unstructured":"Stephansson O, Larsson H, Pedersen L, Kieler H, Granath F, Ludvigsson JF, Falconer H, Ekbom A, Sorensen HT, Norgaard M. Crohn\u2019s disease is a risk factor for preterm birth. Clin Gastroenterol Hepatol 2010;8:509\u2013515.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9948_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3109\/00365521.2013.772229","volume":"48","author":"M Manosa","year":"2013","unstructured":"Manosa M, Navarro-Llavat M, Marin L, Zabana Y, Cabre E, Domenech E. Fecundity, pregnancy outcomes, and breastfeeding in patients with inflammatory bowel disease: a large cohort survey. Scand J Gastroenterol 2013;48:427\u2013432.","journal-title":"Scand J Gastroenterol"},{"key":"9948_CR9","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1111\/j.1572-0241.2007.01355.x","volume":"102","author":"B Norgard","year":"2007","unstructured":"Norgard B, Hundborg HH, Jacobsen BA, Nielsen GL, Fonager K. Disease activity in pregnant women with Crohn\u2019s disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol 2007;102:1947\u20131954.","journal-title":"Am J Gastroenterol"},{"key":"9948_CR10","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/apt.16074","volume":"52","author":"A Meyer","year":"2020","unstructured":"Meyer A, Drouin J, Weill A, Carbonnel F, Dray-Spira R. Pregnancy in women with inflammatory bowel disease: a French nationwide study 2010\u20132018. Aliment Pharmacol Ther 2020;52:1480\u20131490.","journal-title":"Aliment Pharmacol Ther"},{"key":"9948_CR11","first-page":"1091","volume":"20","author":"G Broms","year":"2014","unstructured":"Broms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis 2014;20:1091\u20131098.","journal-title":"Inflamm Bowel Dis"},{"key":"9948_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2022.100104","volume":"3","author":"P Juillerat","year":"2022","unstructured":"Juillerat P, Grueber MM, Ruetsch R, Santi G, Vuillemoz M, Michetti P. Positioning biologics in the treatment of IBD: a practical guide\u2013which mechanism of action for whom? Curr Res Pharmacol Drug Discov 2022;3:100104.","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"9948_CR13","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1136\/gutjnl-2015-309321","volume":"65","author":"A de Lima","year":"2016","unstructured":"de Lima A, Zelinkova Z, van der Ent C, Steegers EA, van der Woude CJ. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut 2016;65:1261\u20131268.","journal-title":"Gut"},{"key":"9948_CR14","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.dld.2024.06.011","volume":"56","author":"S Bendaoud","year":"2024","unstructured":"Bendaoud S, Nahon S, Beaugerie L, Gornet JM, Wils P, Amiot A, Peyrin-Biroulet L, Abitbol V, Hebuterne X, Altwegg R, Rosa I, Amil M, Heluwaert F, Plastaras L, Stefanescu C, Quentin V, Antoni M, Bideau K, Boualit M, Cuillerier E, Locher C, Skinazi F, Boureille A, Buisson A, Simon M. Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: real-world data from a nationwide study. Dig Liver Dis 2024;56:2038\u20132044.","journal-title":"Dig Liver Dis"},{"key":"9948_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cgh.2020.09.021","volume":"20","author":"OH Nielsen","year":"2022","unstructured":"Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C. Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2022;20:74-87 e3.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9948_CR16","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.7326\/M22-0819","volume":"175","author":"A Meyer","year":"2022","unstructured":"Meyer A, Neumann A, Drouin J, Weill A, Carbonnel F, Dray-Spira R. Benefits and risks associated with continuation of anti-tumor necrosis factor after 24 weeks of pregnancy in women with inflammatory bowel disease: a nationwide emulation trial. Ann Intern Med 2022;175:1374\u20131382.","journal-title":"Ann Intern Med"},{"key":"9948_CR17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.cgh.2012.10.024","volume":"11","author":"Z Zelinkova","year":"2013","unstructured":"Zelinkova Z, van der Ent C, Bruin KF, van Baalen O, Vermeulen HG, Smalbraak HJ, Ouwendijk RJ, Hoek AC, van der Werf SD, Kuipers EJ, van der Woude CJ, Dutch Delta IBDG. Effects of discontinuing anti\u2013tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 2013;11:318\u201321.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9948_CR18","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P, U.-I.-U.S. Group. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med 2016;375:1946\u20131960.","journal-title":"N Engl J Med"},{"key":"9948_CR19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A, G.S. Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699\u2013710.","journal-title":"N Engl J Med"},{"key":"9948_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hrobjartsson A, Kirkham J, Juni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schunemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919.","journal-title":"BMJ"},{"key":"9948_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/jrsm.1468","volume":"12","author":"MJ Page","year":"2021","unstructured":"Page MJ, Sterne JAC, Higgins JPT, Egger M. Investigating and dealing with publication bias and other reporting biases in meta-analyses of health research: a review. Res Synth Methods 2021;12:248\u2013259.","journal-title":"Res Synth Methods"},{"key":"9948_CR22","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.14309\/ajg.0000000000000186","volume":"114","author":"ABG Shitrit","year":"2019","unstructured":"Shitrit ABG, Ya\u2019acov AB, Livovsky DM, Cuker T, Farkash R, Hoyda A, Granot T, Avni-Biron I, Lahat A, Goldin E, Grisaru-Granovsky S. Exposure to vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study. Am J Gastroenterol 2019;114:1172\u20131175.","journal-title":"Am J Gastroenterol"},{"key":"9948_CR23","doi-asserted-by":"publisher","first-page":"468","DOI":"10.14309\/ajg.0000000000002553","volume":"119","author":"R Chugh","year":"2024","unstructured":"Chugh R, Long MD, Jiang Y, Weaver KN, Beaulieu DB, Scherl EJ, Mahadevan U. Maternal and neonatal outcomes in vedolizumab- and ustekinumab-exposed pregnancies: results from the PIANO registry. Am J Gastroenterol 2024;119:468\u2013476.","journal-title":"Am J Gastroenterol"},{"key":"9948_CR24","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1093\/ecco-jcc\/jjac086","volume":"16","author":"K Mitrova","year":"2022","unstructured":"Mitrova K, Pipek B, Bortlik M, Bouchner L, Brezina J, Douda T, Drasar T, Klvana P, Kohout P, Leksa V, Minarikova P, Novotny A, Svoboda P, Skorpik J, Ulbrych J, Veinfurt M, Zborilova B, Lukas M, Duricova D, Czech IBDWG. Safety of ustekinumab and vedolizumab during pregnancy-pregnancy, neonatal, and infant outcome: a prospective multicentre study. J Crohns Colitis 2022;16:1808\u20131815.","journal-title":"J Crohns Colitis"},{"key":"9948_CR25","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/apt.16192","volume":"53","author":"P Wils","year":"2021","unstructured":"Wils P, Seksik P, Stefanescu C, Nancey S, Allez M, Pineton de Chambrun G, Altwegg R, Gilletta C, Vuitton L, Viennot S, Serrero M, Fumery M, Savoye G, Collins M, Goutorbe F, Brixi H, Bouguen G, Tavernier N, Boualit M, Amiot A, Abitbol V, Laharie D, Pariente B, P.-G.s. group. Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. Alimentary Pharmacology & Therapeutics 2021;53:460\u2013470.","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"9948_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/apt.15539","volume":"51","author":"A Moens","year":"2020","unstructured":"Moens A, van der Woude CJ, Julsgaard M, Humblet E, Sheridan J, Baumgart DC, Gilletta De Saint-Joseph C, Nancey S, Rahier JF, Bossuyt P, Cremer A, Dewit S, Eriksson C, Hoentjen F, Krause T, Louis E, Macken E, Milenkovic Z, Nijs J, Posen A, Van Hootegem A, Van Moerkercke W, Vermeire S, Bar-Gil Shitrit A, Ferrante M. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther 2020;51:129\u2013138.","journal-title":"Aliment Pharmacol Ther"},{"key":"9948_CR27","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/apt.17224","volume":"56","author":"I Avni-Biron","year":"2022","unstructured":"Avni-Biron I, Mishael T, Zittan E, Livne-Margolin M, Zinger A, Tzadok R, Goldenberg R, Kopylov U, Ron Y, Hadar E, Helman S, Granovsky SG, Ollech JE, Arazi A, Farkash R, Pauker MH, Yanai H, Dotan I, Shitrit AB. Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther 2022;56:1361\u20131369.","journal-title":"Aliment Pharmacol Ther"},{"key":"9948_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cgh.2024.02.025","volume":"23","author":"R Prentice","year":"2025","unstructured":"Prentice R, Flanagan E, Wright EK, Gibson PR, Rosella S, Rosella O, Begun J, An YK, Lawrance IC, Kamm MA, Sparrow M, Goldberg R, Prideaux L, Vogrin S, Kiburg KV, Ross AL, Burns M, Bell SJ. Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero. Clin Gastroenterol Hepatol 2025;23:124-133 e7.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9948_CR29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cgh.2023.12.029","volume":"23","author":"A Meyer","year":"2025","unstructured":"Meyer A, Miranda S, Drouin J, Weill A, Carbonnel F, Dray-Spira R. Safety of Vedolizumab and ustekinumab compared with anti-TNF in pregnant women with inflammatory bowel disease. Clin Gastroenterol Hepatol 2025;23:144-153 e22.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9948_CR30","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/apt.16102","volume":"52","author":"E Flanagan","year":"2020","unstructured":"Flanagan E, Gibson PR, Wright EK, Moore GT, Sparrow MP, Connell W, Kamm MA, Begun J, Christensen B, De Cruz P, Shelton E, Dowling D, Andrews JM, Brown SJ, Niewiadomski O, Ward MG, Rosella O, Rosella G, Kiburg KV, Ross AL, Bell SJ, P.S. Group. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther 2020;52:1551\u20131562.","journal-title":"Aliment Pharmacol Ther"},{"key":"9948_CR31","doi-asserted-by":"crossref","unstructured":"Zhao, S., S. Zhou, J. Wang, and Y. Shi, When inflammatory bowel disease meets pregnancy. Eur J Intern Med, 2025.","DOI":"10.1016\/j.ejim.2025.06.014"},{"key":"9948_CR32","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1053\/j.gastro.2020.11.050","volume":"160","author":"ES Kim","year":"2021","unstructured":"Kim ES, Tarassishin L, Eisele C, Barre A, Nair N, Rendon A, Hawkins K, Debebe A, White S, Thjomoe A, Mork E, Bento-Miranda M, Panchal H, Agrawal M, Patel A, Chen CL, Kornbluth A, George J, Legnani P, Maser E, Loudon H, Mella MT, Stone J, Dubinsky M, Sabino J, Torres J, Colombel JF, Peter I, Hu J, G. Mount Sinai Road to Prevention Study. Longitudinal changes in fecal calprotectin levels among pregnant women with and without inflammatory bowel disease and their babies. Gastroenterology 2021;160:1118-1130 e3.","journal-title":"Gastroenterology"},{"key":"9948_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/17474124.2021.1876562","volume":"15","author":"D Guerrero Vinsard","year":"2021","unstructured":"Guerrero Vinsard D, Kane SV. Biologics and pregnancy: a clinician\u2019s guide to the management of IBD in pregnant women. Expert Rev Gastroenterol Hepatol 2021;15:633\u2013641.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"9948_CR34","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/gutjnl-2019-318263","volume":"69","author":"J van der Giessen","year":"2020","unstructured":"van der Giessen J, Binyamin D, Belogolovski A, Frishman S, Tenenbaum-Gavish K, Hadar E, Louzoun Y, Peppelenbosch MP, van der Woude CJ, Koren O, Fuhler GM. Modulation of cytokine patterns and microbiome during pregnancy in IBD. Gut 2020;69:473\u2013486.","journal-title":"Gut"},{"key":"9948_CR35","doi-asserted-by":"crossref","unstructured":"Pedersen, N., A. Bortoli, D. Duricova, D.I. R, M.R. Panelli, J.P. Gisbert, G. Zoli, A. Lopez-Sanroman, F. Castiglione, G. Riegler, V. Annese, P. Gionchetti, A. Prada, E.D. Pont, A. Timmer, C. Felley, M. Shuhaibar, E.V. Tsianos, C. Dejaco, F.J. Baert, T. Jess, M. Lebech, D.W. Hommes, P. Munkholm, and E.-S.G.o.E.C.-E. European Crohn-Colitis Organisation, The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women. Aliment Pharmacol Ther, 2013. 38(5): p. 501\u201312.","DOI":"10.1111\/apt.12412"},{"key":"9948_CR36","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/ibd\/izaa096","volume":"27","author":"A Yu","year":"2021","unstructured":"Yu A, Friedman S, Ananthakrishnan AN. Characteristics and long-term outcomes of pregnancy-onset inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2021;27:476\u2013481.","journal-title":"Inflamm Bowel Dis"},{"key":"9948_CR37","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1517\/14740338.2012.720970","volume":"11","author":"S Saha","year":"2012","unstructured":"Saha S, Wald A. Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease. Expert Opin Drug Saf 2012;11:947\u2013957.","journal-title":"Expert Opin Drug Saf"},{"key":"9948_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.14309\/ajg.0000000000000910","volume":"116","author":"J Gubatan","year":"2021","unstructured":"Gubatan J, Nielsen OH, Levitte S, Juhl CB, Maxwell C, Streett SE, Habtezion A. Biologics during pregnancy in women with inflammatory bowel disease and risk of infantile infections: a systematic review and meta-analysis. Am J Gastroenterol 2021;116:243\u2013253.","journal-title":"Am J Gastroenterol"},{"key":"9948_CR39","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1097\/MIB.0000000000000092","volume":"20","author":"N Narula","year":"2014","unstructured":"Narula N, Al-Dabbagh R, Dhillon A, Sands BE, Marshall JK. Anti-TNFalpha therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2014;20:1862\u20131869.","journal-title":"Inflamm Bowel Dis"},{"key":"9948_CR40","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","volume":"160","author":"U Mahadevan","year":"2021","unstructured":"Mahadevan U, Long MD, Kane SV, Roy A, Dubinsky MC, Sands BE, Cohen RD, Chambers CD, Sandborn WJ, A. Crohn\u2019s Colitis Foundation Clinical Research. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology 2021;160:1131\u20131139.","journal-title":"Gastroenterology"},{"key":"9948_CR41","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.dld.2017.07.010","volume":"49","author":"JO Lindsay","year":"2017","unstructured":"Lindsay JO, Armuzzi A, Gisbert JP, Bokemeyer B, Peyrin-Biroulet L, Nguyen GC, Smyth M, Patel H. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2017;49:1086\u20131091.","journal-title":"Dig Liver Dis"},{"key":"9948_CR42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/ibd\/izz110","volume":"26","author":"M Julsgaard","year":"2020","unstructured":"Julsgaard M, Hvas CL, Gearry RB, Gibson PR, Fallingborg J, Sparrow MP, Bibby BM, Connell WR, Brown SJ, Kamm MA, Lawrance IC, Vestergaard T, Svenningsen L, Baekdal M, Kammerlander H, Walsh A, Boysen T, Bampton P, Radford-Smith G, Kjeldsen J, Andrews JM, Subramaniam K, Moore GT, Jensen NM, Connor SJ, Wildt S, Wilson B, Ellard K, Christensen LA, Bell SJ. Anti-TNF therapy in pregnant women with inflammatory bowel disease: effects of therapeutic strategies on disease behavior and birth outcomes. Inflamm Bowel Dis 2020;26:93\u2013102.","journal-title":"Inflamm Bowel Dis"},{"key":"9948_CR43","doi-asserted-by":"publisher","first-page":"13205","DOI":"10.3748\/wjg.v21.i47.13205","volume":"21","author":"I Androulakis","year":"2015","unstructured":"Androulakis I, Zavos C, Christopoulos P, Mastorakos G, Gazouli M. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease. World J Gastroenterol 2015;21:13205\u201313211.","journal-title":"World J Gastroenterol"},{"key":"9948_CR44","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1155\/2014\/967598","volume":"28","author":"Y Leung","year":"2014","unstructured":"Leung Y, Panaccione R, Ghosh S, Seow CH. Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions. Can J Gastroenterol Hepatol 2014;28:505\u2013509.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"9948_CR45","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/apt.13960","volume":"45","author":"U Mahadevan","year":"2017","unstructured":"Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, Dubinsky M. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther 2017;45:941\u2013950.","journal-title":"Aliment Pharmacol Ther"},{"key":"9948_CR46","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ajog.2019.02.027","volume":"220","author":"U Mahadevan","year":"2019","unstructured":"Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M, Friedman S, Kane S, Manthey J, Sauberan J, Stone J, Jain R. inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD parenthood project working group. Am J Obstet Gynecol 2019;220:308\u2013323.","journal-title":"Am J Obstet Gynecol"},{"key":"9948_CR47","doi-asserted-by":"crossref","unstructured":"Nguyen, G.C., C.H. Seow, C. Maxwell, V. Huang, Y. Leung, J. Jones, G.I. Leontiadis, F. Tse, U. Mahadevan, C.J. van der Woude, I.B.D.i.P.C. Group, and G. Canadian Association of, The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology, 2016. 150(3): p. 734\u2013757 e1.","DOI":"10.1053\/j.gastro.2015.12.003"},{"key":"9948_CR48","doi-asserted-by":"crossref","unstructured":"Nguyen, B., S. Quon, A.J. Williams, and Y. Leung, Safety of Vedolizumab in Pregnancy: An Updated Systematic Review and Comprehensive Meta-analysis. J Clin Gastroenterol, 2025.","DOI":"10.1097\/MCG.0000000000002310"},{"key":"9948_CR49","doi-asserted-by":"crossref","unstructured":"Chambers, C.D., D.L. Johnson, Y. Luo, R. Xu, M.P. Adam, S.R. Braddock, K.L. Jones, and O.C.R. Group, Birth Outcomes in Women Who Have Taken Vedolizumab in Pregnancy: Results From the Vedolizumab Pregnancy Exposure Registry. Am J Gastroenterol, 2025.","DOI":"10.14309\/ajg.0000000000003593"},{"key":"9948_CR50","doi-asserted-by":"crossref","unstructured":"Zwicker, S., R. Lira-Junior, C. Hoog, S. Almer, and E.A. Bostrom, Systemic Chemokine Levels with \"Gut-Specific\" Vedolizumab in Patients with Inflammatory Bowel Disease-A Pilot Study. Int J Mol Sci, 2017. 18(8).","DOI":"10.3390\/ijms18081827"},{"key":"9948_CR51","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/ibd\/izac056","volume":"28","author":"A Blaisdell","year":"2022","unstructured":"Blaisdell A, Zhou Y, Kattah MG, Fisher SJ, Mahadevan U. Vedolizumab antagonizes MAdCAM-1-dependent human placental cytotrophoblast adhesion and invasion in vitro. Inflamm Bowel Dis 2022;28:1219\u20131228.","journal-title":"Inflamm Bowel Dis"},{"key":"9948_CR52","doi-asserted-by":"publisher","first-page":"175628482110327","DOI":"10.1177\/17562848211032790","volume":"14","author":"K Mitrova","year":"2021","unstructured":"Mitrova K, Pipek B, Bortlik M, Bouchner L, Brezina J, Douda T, Drasar T, Drastich P, Falt P, Klvana P, Leksa V, Novotny A, Svoboda P, Skorpik J, Ulbrych J, Veinfurt M, Zborilova B, Lukas M, Duricova D. Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study. Therap Adv Gastroenterol 2021;14:17562848211032790.","journal-title":"Therap Adv Gastroenterol"},{"key":"9948_CR53","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1111\/jgh.15574","volume":"36","author":"C Bell","year":"2021","unstructured":"Bell C, Tandon P, Lentz E, Marshall JK, Narula N. Systematic review and meta-analysis: safety of vedolizumab during pregnancy in patients with inflammatory bowel disease. J Gastroenterol Hepatol 2021;36:2640\u20132648.","journal-title":"J Gastroenterol Hepatol"},{"key":"9948_CR54","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.dld.2022.08.028","volume":"55","author":"FS Macaluso","year":"2023","unstructured":"Macaluso FS, Grova M, Saladino M, Cappello M, Demarzo MG, Privitera AC, Giangreco E, Garufi S, Renna S, Casa A, Ventimiglia M, Fries W, Orlando A, D. Sicilian Network for Inflammatory Bowel. The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn\u2019s disease. Dig Liver Dis 2023;55:471\u2013477.","journal-title":"Dig Liver Dis"},{"key":"9948_CR55","doi-asserted-by":"publisher","first-page":"175628482110724","DOI":"10.1177\/17562848211072412","volume":"15","author":"ML Scribano","year":"2022","unstructured":"Scribano ML, Aratari A, Neri B, Bezzio C, Balestrieri P, Baccolini V, Falasco G, Camastra C, Pantanella P, Monterubbianesi R, Tullio A, Saibeni S, Papi C, Biancone L, Cosintino R, Faggiani R. Effectiveness of ustekinumab in patients with refractory Crohn\u2019s disease: a multicentre real-life study in Italy. Therap Adv Gastroenterol 2022;15:17562848211072412.","journal-title":"Therap Adv Gastroenterol"},{"key":"9948_CR56","doi-asserted-by":"publisher","first-page":"60","DOI":"10.14309\/ajg.0000000000001963","volume":"117","author":"E Shmidt","year":"2022","unstructured":"Shmidt E, Dubinsky MC. Inflammatory bowel disease and pregnancy. Am J Gastroenterol 2022;117:60\u201368.","journal-title":"Am J Gastroenterol"},{"key":"9948_CR57","doi-asserted-by":"publisher","first-page":"175628482110162","DOI":"10.1177\/17562848211016242","volume":"14","author":"R Laube","year":"2021","unstructured":"Laube R, Paramsothy S, Leong RW. Review of pregnancy in Crohn\u2019s disease and ulcerative colitis. Therap Adv Gastroenterol 2021;14:17562848211016242.","journal-title":"Therap Adv Gastroenterol"},{"key":"9948_CR58","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12884-024-06443-w","volume":"24","author":"W Huang","year":"2024","unstructured":"Huang W, Zhang X, Zhang L, Dai X, Chen H, Xie Q. Anti-tumor necrosis factor-alpha therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review. BMC Pregnancy Childbirth 2024;24:251.","journal-title":"BMC Pregnancy Childbirth"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09948-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-09948-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09948-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:36:01Z","timestamp":1789014961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-09948-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["9948"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-09948-w","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"24 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a systematic review and meta-analysis of previously published data. No new human or animal subjects were involved; therefore, institutional review board approval was not required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}